A review on toxic epidermal necrolysis‐like superficial wound lesions: Issue and challenge on 10 clinical entities Authors: Bahareh Abtahi‐Naeini, Mahsa Pourmahdi‐Boroujeni, Fereshte Rastegarnasab, Ali Emamjomeh Published: 2024 ABSTRACT AbstractToxic epidermal necrolysis (TEN) is a severe skin reaction caused by extensive epidermal and mucosal necrosis. This clinical phenomenon is known as an acute syndrome of apoptotic pan‐epidermolysis (ASAP). The ASAP phenomenon is observed in conditions that mimic TEN, highlighting the challenge in distinguishing these conditions. While TEN is a well‐recognized entity, distinguishing it from other TEN‐like conditions presents significant diagnostic and treatment challenges. These conditions include drug rash with eosinophilia and systemic symptoms (DRESS), generalized bullous fixed drug eruption (GBFDE), acute generalized exanthematous pustulosis (AGEP), TEN‐like methotrexate toxicity, mustard gas toxicity, pseudoporphyria, mycoplasma‐induced rash and mucositis (MIRM), multisystem inflammatory syndrome in children (MIS‐C), graft versus host disease (GVHD), and acute cutaneous lupus erythematosus and subacute cutaneous lupus erythematosus. This review explores these ten separate entities and debates their clinical features, pathophysiology, diagnosis and management. Abbreviations acute generalized exanthematous pustulosis acute syndrome of apoptotic pan‐epidermolysis antithymocyte globulin body surface area cluster of differentiation calcineurin inhibitors drug‐induced hypersensitivity syndrome drug rash with eosinophilia and systemic signs extracorporeal photopheresis enzyme‐linked immunoassays food and drug administration fixed drug eruptions generalized bullous fixed drug eruption granulocyte‐colony stimulating factor graft versus host disease human Herpesvirus‐6 interferon‐gamma immunoglobulin M interleukin‐1 interleukin‐6 interleukin‐8 intravenous immunoglobulin Kawasaki disease macrophage activation syndrome mycoplasma pneumoniae‐induced rash and mucositis multisystem inflammatory syndrome in children mycoplasma pneumoniae methotrexate non‐steroidal anti‐inflammatory drugs polymerase chain reaction reactive oxygen species severe acute respiratory syndrome Coronavirus 2 secondary hemophagocytic lymph histiocytosis Stevens‐Johnson syndrome systemic lupus erythematosus sulphur mustard gas toxic epidermal necrolysis tumour necrosis factor‐alpha toxic shock syndrome INTRODUCTION Toxic epidermal necrolysis (TEN) is a rare, acute, severe, unpredictable and potentially fatal skin medical emergency related to extensive necrosis of the epidermis and mucosa, which presents as sheet‐like skin detachment and mucositis due to drug reaction. 1 , 2 In 2004, Ting and colleagues introduced the acute syndrome of apoptotic pan‐epidermolysis (ASAP) to describe the clinical characteristics of TEN and some TEN‐like diseases. 3 ASAP is a clinical phenomenon identified by acute and significant epidermal cleavage from hyperacute apoptotic injury of epidermal basal cells. Clinical findings are characterized by acute full‐thickness epidermal detachment, as in TEN cases, and subepidermal vesiculobullous formation. 3 In addition to TEN, the ASAP phenomenon might be presented in other diseases that resemble TEN, known as TEN‐like conditions. These TEN‐like conditions can be very similar to the clinical presentation of TEN. 4 Identifying and differentiating them are essential as they have different aetiology, diagnoses and therapeutic choices. This review will explore 10 distinct conditions that share clinical similarities with TEN but require different management approaches. These include drug rash with eosinophilia and systemic symptoms (DRESS), generalized bullous fixed drug eruption (GBFDE), acute generalized exanthematous pustulosis (AGEP), TEN‐like methotrexate toxicity, Mustard gas toxicity, pseudoporphyria, mycoplasma‐induced rash and mucositis (MIRM), multisystem inflammatory syndrome in children (MIS‐C), graft versus host disease (GVHD), and acute cutaneous lupus erythematosus and subacute cutaneous lupus erythematosus. To the best of our knowledge, no review has comprehensively discussed TEN‐like entities. Hence, the objective of this review is to offer a thorough summary of the clinical symptoms, pathogenesis process, identification and available treatment alternatives for each of these conditions while also comparing them with TEN. METHODS The search was performed in PubMed, Scopus, Web of Science and Google Scholar to find papers reporting detailed clinical descriptions of patients diagnosed with conditions resembling TEN. The search was conducted up to June 2024 using the following keywords: ‘drug rash with eosinophilia and systemic symptoms,’ ‘DRESS,’ ‘generalized bullous fixed drug eruption,’ ‘GBFDE,’ ‘acute generalized exanthematous pustulosis,’ ‘AGEP,’ ‘methotrexate toxicity,’ ‘mustard toxicity,’ ‘pseudoporphyria,’ ‘graft versus host disease,’ ‘GVHD,’ ‘lupus erythematosus,’ ‘mycoplasma‐induced rash and mucositis,’ ‘MIRM,’ ‘multisystem inflammatory syndrome in children,’ ‘MIS‐C,’ ‘acute syndrome of apoptotic pan‐epidermolysis,’ ‘ASAP,’ ‘toxic epidermal necrolysis’ and ‘TEN.’ The inclusion criteria were all types of publications in English, including systematic reviews, randomized clinical trials, observational studies, case series and case reports. The articles included in this review were selected based on their relevance to TEN and TEN‐like conditions. Data extraction focused on the clinical features, pathophysiological mechanisms, diagnostic criteria and management strategies of each condition. We specifically extracted data on the presentation of skin and mucosal lesions, associated systemic symptoms, potential triggers and differences in clinical progression. Additionally, diagnostic approaches, including laboratory findings and histopathological characteristics, were reviewed. Management approaches were summarized based on reported treatment strategies, including both first‐line and supportive therapies, as well as any reported outcomes. The extracted information was synthesized to provide a comparative overview of TEN and TEN‐like conditions, highlighting key similarities and differences. DISCUSSION TEN, a severe medical skin emergency, shares similarities with Stevens–Johnson syndrome (SJS) and affects over 30% of the body surface area (BSA). SJS, on the other hand, involves <10% of the BSA. If the BSA involvement falls between 10% and 30%, it is classified as SJS/TEN overlap. 1 , 2 TEN is almost always associated with the consumption of a culprit drug and typically develops within 2–4 days, up to 1 month, after the initiation of the offending medication. 1 , 5 Infections, such as viral conditions, may play a possible but weak role. 1 , 5 , 6 The clinical presentation consists of a prodromal phase with fever, malaise, sore throat and cough. Subsequently, there is universal epidermal involvement with diffuse erythema, atypical target lesions, erythematous macules with dusky centres, flaccid blisters and large epidermal sheet‐like detachment with a positive Nikolsky's sign. Mucosal membranes, especially oral ones, get involved in up to 100% of cases. In most cases, there is also eye involvement, which can range from conjunctivitis to corneal sloughing. 1 , 5 The pathophysiology of TEN is not yet fully understood. Type IV hypersensitivity reactions and T‐cell‐mediated reactions are involved in this condition, with the drug or infection activating T cells, which in turn causes epidermis necrosis. There is a hypothesis that keratinocyte death is medicated by Fas/Fas ligand interactions. In addition, granulysin, a cytolytic and pro‐inflammatory molecule, is one of the main drivers of epidermal necrosis. Intrinsic factors produced by the keratinocytes lead to the production of tumour necrosis factor‐alpha (TNF‐ α), causing further damage. 5 , 6 Also, eosinophilic necrosis of the epidermis is found in the peak stage. 7 Anticonvulsants, allopurinol, various antibiotics, sulfonamides and non‐steroidal anti‐inflammatory drugs (NSAIDs) are the main offending causes. Diagnosis requires a history of suspected drug use along with full‐thickness epidermal necrosis and a negative result on the direct immunofluorescence tests. 1 , 5 , 6 When drug consumption is suspected, the diagnosis should be determined by considering the clinical evidence. An accurate diagnosis necessitates a skin biopsy, but this procedure is typically not carried out. The histological examination shows complete necrosis of keratinocytes throughout the depth of the epidermis, along with subepithelial blisters and vacuolization of the basal membrane. 1 , 4 , 5 Multidisciplinary management is essential in treating TEN. Early diagnosis, cessation of the suspected medication and supportive care are crucial for improving the prognosis. Systemic treatment options include corticosteroids, intravenous immunoglobulin (IVIG) and cyclosporine. 6 However, the benefits and differences among these options remain controversial. 5 , 6 As mentioned before, some differential diagnoses can closely resemble the clinical presentation of TEN. 4 It is essential to identify and differentiate these conditions as they have different aetiologies, diagnoses and therapeutic choices. Table 1 shows a comparative overview of TEN and TEN‐like diseases (Table 1). In the following section, each of these conditions is compared with TEN. TABLE 1A comparative overview of TEN and TEN‐like disease.DiseaseClinical ManifestationsPathogenesisDiagnosisTreatment TEN 3 days to 3 weeks after drug consumption Presence of prodromal phase Mucocutaneous: Lesions begin at the trunk and spread distally, Diffuse erythema, atypical target lesions, Erythematous macules with dusky centers, Flaccid blisters, Vesiculobullous lesions, Large epidermal sheets, Positive Nikolsky's sign, Mucosal involvement especially oral mucosa, Conjunctivitis to corneal sloughing Type IV hypersensitivity reactions ↑TNF‐a, ↑Granulysin Fas–Fas ligand interactions, ↑IL10, ↑IL6, Keratinocytes death Culprit drugs: Anticonvulsants, Allopurinol, Antibiotics, Sulfonamides, NSAIDs, Immunotherapy agents History of suspected drug consumption with full‐thickness epidermal necrosis and a negative direct immunofluorescence test, Definitive diagnosis requires histological analysis, Leukopenia, Lymphopenia Histopathology: Keratinocyte necrosis, Perivascular & discrete lymphohistiocytic and inflammatory infiltrate in the superficial dermis, Subepidermal bullae, Subepithelial & basal membrane vacuolization Cessation of culprit drug consumptionSupportive careIVIG TEN‐like DRESS 2–6 weeks after drug consumption Presence of prodromal phase Mucocutaneous: Skin of acral parts: Limbs, Face Mild mucositis Systemic: Fever, Internal organ involvement, Lymph node enlargement, Nephritis, Severe liver involvement, Myocarditis, Pericarditis, Pneumonia Drug‐specific T‐cell activation, HHV‐6 reactivation, Antiviral immune responses Culprit drugs: Phenytoin, Phenobarbital, Carbamazepine, Sulfonamides Different skin manifestation from TEN History of specific culprit drug consumption, Eosinophilia, Leukocytosis, Lymphocytosis, Elevated liver enzymes Histopathology: Not specific Cessation of culprit drug consumptionSupportive careCorticosteroids TEN‐like GBFDE 30 min to 1 day after drug consumption Mucocutaneous: Identical lesion recurrence at the same sites, Underlying reddish‐brown to brownish‐grey discoloration & overlying bullae on diffuse hyperpigmentation, Mild mucous membrane involvement Systemic: No particular involvement Type IV hypersensitivity reactions Activation of intradermal CD8+ T cells with more dermal CD4+ and Foxp3+ cell infiltration Culprit drugs: Cephalosporins, Penicillins, NSAIDs Previous history of FDE to a specific drug, Patch test if the clinical history is unclear Histopathology: Individual apoptotic keratinocytes throughout the epidermis, Prominent dermal eosinophilic & lymphocytic infiltration, Dermal melanophages Cessation of culprit drug consumptionSupportive careCorticosteroids (short course) TEN‐like AGEP Within 24 h after drug consumption Mucocutaneous: Small pustules on an erythematous background, pseudo‐positive Nikolsky's sign Systemic: Fever, Leukocytosis Type IV hypersensitivity reactions Production of chemokines is more significant Culprit drugs: Antibiotics, NSAIDs, Opioids, Antiepileptics, Hydroxychloroquine, Chemotherapy agents Clinical manifestations, Onset of manifestations Histopathology: Spongiform subcorneal and intraepidermal pustules edema of the dermis, Necrosis of single keratinocytes, Infiltrate of neutrophils & eosinophils with perivascular accentuation Cessation of culprit drug consumptionSupportive careCorticosteroids TEN‐like Methotrexate‐Toxicity Any time after drug consumption Mucocutaneous: Painful skin erosions, Multiple skin detachments, Without target‐like lesions, Oral ulcers Systemic: Pancytopenia MTX, functioning as a folic acid Antagonist & impeding DNA synthesis, can lead to cell death by its cytotoxic effects, Absence of upregulation of inflammatory mediators Associated risk factors: Renal function impairment, Co‐administration with other drugs, Elderly, High‐dose therapeutic regime History of MTX consumption, especially a high dose regime, Leukopenia, Thrombocytopenia, Histopathology: Non‐specific keratinocyte dystrophy, Epidermal necrosis, Epidermal atrophy Cessation of culprit drug consumptionSupportive careLeucovorinCarboxypeptidaseG‐CSFDialysis TEN‐like Sulphur mustard gas toxicity Mucocutaneous: Oily substance on the skin, Pruritus, light erythema, Bullae, Necrosis, typically affect folds of body Urogenital & Mucosal & Ocular involvement Systemic: Rhinorrhea, Epistaxis, Dyspnea, Pulmonary edema, Nausea and vomiting, Abdominal pain, Dysentery, Severe dehydration DNA alkylation, Activating apoptosis and necrosis, Oxidative stress, Capillary thrombi formation SM exposure & rapid onset of clinical symptoms Histopathology: Detachment of the epidermis, subepidermal blisters, and epidermis necrosis, undifferentiable from TEN Cleaning & washing the skinAntibioticsSupportive careTopical corticosteroids TEN‐like Pseudoporphyria Mucocutaneous: Widespread necrobullous eruptions, Profound & painful blisters on the fingertips & sun‐exposed areas, less aggressive mucosal membrane involvement Systemic: Normal levels of porphyrin, Porphyrins accumulation in chronic haemodialysis Culprit drugs: NSAIDs, Furosemide, Nalidixic acid, Tetracycline, Pyridoxine, Isotretinoin, Tyrosine kinase inhibitors Clinical presentations especially in chronic haemodialysis syndrome, NL porphyrin levels in serum & urine & faeces Histopathology: Resemble porphyria cutanea tarda, Inflammatory infiltration, Thickening of venular walls, Deposition of immunoglobulins C3 & IgG at the epidermal‐dermal junction Supportive careN‐acetylcysteineCessation of possible culprit drug consumptionSun protectionPeritoneal dialysis TEN‐like MIRM Affecting young men and children Presence of prodromal phase Mucocutaneous: Prominent mucositis including ulcers & erosions, Pleomorphic lesions including macules and papules and atypical targetoid and vesiculobullous lesions, Ocular involvement, Purulent bilateral conjunctivitis Systemic: Atypical pneumonia, Cold antibody haemolytic anaemia Mycoplasma pneumoniae B cell activation, AB production, Cutaneous immune complex deposition, Complement formation, Molecular mimicry in keratinocyte antigen and Mycoplasma adhesion molecules Clinical presentations, Radiological features of MP infection, Lack of culprit drug history in a pneumonia setting, Cold agglutinins, MP IgM antibody, Leukocytosis, Shift to the left, PCR Histopathology: Histopathological similarities to TEN Antibiotic therapySupportive careCorticosteroidsIVIG TEN‐like MIS‐C Mucocutaneous: Polymorphic, Maculopapular, Morbilliform, Diffuse erythroderma, Dry & red lips, Mucosal changes, Hand & feet erythema, Edema, Blistering skin lesions Systemic: Fever, Multisystem organ involvement, Laboratory evidence of hyperinflammatory response SARS‐COV2 TEN‐like clinical presentations in a setting of confirmed MIS‐C, Lack of culprit drug history Histopathology: Histopathological similarities to TEN Supportive careCorticosteroidsIVIGTocilizumabAtazanavir TEN‐like Sever GVHD Two weeks after transplantation Mucocutaneous: Diffuse erythroderma, Bulla formation, Desquamation, Full‐thickness epidermal necrosis (Grade IV), Beginning from acral site & spreading proximally Systemic: Affecting Liver, Gut, Thymus Predominance of CD8+ T lymphocytes, GVHD has more inflammation than TEN does Histopathology: Skin biopsy has low sensitivity & specificity Supportive careCorticosteroidsTNF antagonistMycophenolate MofetilAntithymocyte GlobulinAnti‐il‐2r antibodiesPhototherapy TEN‐like Lupus Without prodromal phase Mucocutaneous: Massive epidermal cleavage & cutaneous necrosis, Vesicobullous changes, Subepidermal blistering, Sun‐exposed area, Without target‐like lesions, Mucosal membrane involvement Systemic: Other presentations of lupus Ultraviolet light plays a role in inducing keratinocyte apoptosis, ↑ IL6 & IL10, Upregulation of Fas and Fas–Fas ligand interactions Clinical presentations, Absence of suitable drug consumption history, Laboratory data Histopathology: Basal layer vacuolation, Keratinocyte apoptosis, Full‐thickness epidermal necrosis, Dyskeratosis extending down adnexae, Presence of lupus band at the dermo‐epidermal junction in IHC, including granular IgG, IgM, C3 blinding Supportive careCorticosteroidsIVIGMycophenolate Mofetil Abbreviations: AGEP, acute generalized exanthematous pustulosis; DRESS, drug rash with eosinophilia and systemic symptoms; GBFDE, generalized bullous fixed drug eruption; GVHD, graft versus host disease; MIRM, mycoplasma‐induced rash and mucositis; MIS‐C, multisystem inflammatory syndrome in children; TEN, toxic epidermal necrolysis. A comparative overview of TEN and TEN‐like disease. 3 days to 3 weeks after drug consumption Presence of prodromal phase Mucocutaneous: Lesions begin at the trunk and spread distally, Diffuse erythema, atypical target lesions, Erythematous macules with dusky centers, Flaccid blisters, Vesiculobullous lesions, Large epidermal sheets, Positive Nikolsky's sign, Mucosal involvement especially oral mucosa, Conjunctivitis to corneal sloughing Type IV hypersensitivity reactions ↑TNF‐a, ↑Granulysin Fas–Fas ligand interactions, ↑IL10, ↑IL6, Keratinocytes death Culprit drugs: Anticonvulsants, Allopurinol, Antibiotics, Sulfonamides, NSAIDs, Immunotherapy agents History of suspected drug consumption with full‐thickness epidermal necrosis and a negative direct immunofluorescence test, Definitive diagnosis requires histological analysis, Leukopenia, Lymphopenia Histopathology: Keratinocyte necrosis, Perivascular & discrete lymphohistiocytic and inflammatory infiltrate in the superficial dermis, Subepidermal bullae, Subepithelial & basal membrane vacuolization Cessation of culprit drug consumptionSupportive careIVIG Cessation of culprit drug consumption Cessation of culprit drug consumption Supportive care Supportive care IVIG IVIG 2–6 weeks after drug consumption Presence of prodromal phase Mucocutaneous: Skin of acral parts: Limbs, Face Mild mucositis Systemic: Fever, Internal organ involvement, Lymph node enlargement, Nephritis, Severe liver involvement, Myocarditis, Pericarditis, Pneumonia Drug‐specific T‐cell activation, HHV‐6 reactivation, Antiviral immune responses Culprit drugs: Phenytoin, Phenobarbital, Carbamazepine, Sulfonamides Different skin manifestation from TEN History of specific culprit drug consumption, Eosinophilia, Leukocytosis, Lymphocytosis, Elevated liver enzymes Histopathology: Not specific Cessation of culprit drug consumption Cessation of culprit drug consumption Supportive care Supportive care Corticosteroids Corticosteroids 30 min to 1 day after drug consumption Mucocutaneous: Identical lesion recurrence at the same sites, Underlying reddish‐brown to brownish‐grey discoloration & overlying bullae on diffuse hyperpigmentation, Mild mucous membrane involvement Systemic: No particular involvement Type IV hypersensitivity reactions Activation of intradermal CD8+ T cells with more dermal CD4+ and Foxp3+ cell infiltration Culprit drugs: Cephalosporins, Penicillins, NSAIDs Previous history of FDE to a specific drug, Patch test if the clinical history is unclear Histopathology: Individual apoptotic keratinocytes throughout the epidermis, Prominent dermal eosinophilic & lymphocytic infiltration, Dermal melanophages Cessation of culprit drug consumption Cessation of culprit drug consumption Supportive care Supportive care Corticosteroids (short course) Corticosteroids (short course) Within 24 h after drug consumption Mucocutaneous: Small pustules on an erythematous background, pseudo‐positive Nikolsky's sign Systemic: Fever, Leukocytosis Type IV hypersensitivity reactions Production of chemokines is more significant Culprit drugs: Antibiotics, NSAIDs, Opioids, Antiepileptics, Hydroxychloroquine, Chemotherapy agents Clinical manifestations, Onset of manifestations Histopathology: Spongiform subcorneal and intraepidermal pustules edema of the dermis, Necrosis of single keratinocytes, Infiltrate of neutrophils & eosinophils with perivascular accentuation Cessation of culprit drug consumption Cessation of culprit drug consumption Supportive care Supportive care Corticosteroids Corticosteroids Any time after drug consumption Mucocutaneous: Painful skin erosions, Multiple skin detachments, Without target‐like lesions, Oral ulcers Systemic: Pancytopenia MTX, functioning as a folic acid Antagonist & impeding DNA synthesis, can lead to cell death by its cytotoxic effects, Absence of upregulation of inflammatory mediators Associated risk factors: Renal function impairment, Co‐administration with other drugs, Elderly, High‐dose therapeutic regime History of MTX consumption, especially a high dose regime, Leukopenia, Thrombocytopenia, Histopathology: Non‐specific keratinocyte dystrophy, Epidermal necrosis, Epidermal atrophy Cessation of culprit drug consumption Cessation of culprit drug consumption Supportive care Supportive care Leucovorin Leucovorin Carboxypeptidase Carboxypeptidase G‐CSF G‐CSF Dialysis Dialysis Mucocutaneous: Oily substance on the skin, Pruritus, light erythema, Bullae, Necrosis, typically affect folds of body Urogenital & Mucosal & Ocular involvement Systemic: Rhinorrhea, Epistaxis, Dyspnea, Pulmonary edema, Nausea and vomiting, Abdominal pain, Dysentery, Severe dehydration SM exposure & rapid onset of clinical symptoms Histopathology: Detachment of the epidermis, subepidermal blisters, and epidermis necrosis, undifferentiable from TEN Cleaning & washing the skin Cleaning & washing the skin Antibiotics Antibiotics Supportive care Supportive care Topical corticosteroids Topical corticosteroids Mucocutaneous: Widespread necrobullous eruptions, Profound & painful blisters on the fingertips & sun‐exposed areas, less aggressive mucosal membrane involvement Systemic: Normal levels of porphyrin, Porphyrins accumulation in chronic haemodialysis Culprit drugs: NSAIDs, Furosemide, Nalidixic acid, Tetracycline, Pyridoxine, Isotretinoin, Tyrosine kinase inhibitors Clinical presentations especially in chronic haemodialysis syndrome, NL porphyrin levels in serum & urine & faeces Histopathology: Resemble porphyria cutanea tarda, Inflammatory infiltration, Thickening of venular walls, Deposition of immunoglobulins C3 & IgG at the epidermal‐dermal junction Supportive care Supportive care N‐acetylcysteine N‐acetylcysteine Cessation of possible culprit drug consumption Cessation of possible culprit drug consumption Sun protection Sun protection Peritoneal dialysis Peritoneal dialysis Affecting young men and children Presence of prodromal phase Mucocutaneous: Prominent mucositis including ulcers & erosions, Pleomorphic lesions including macules and papules and atypical targetoid and vesiculobullous lesions, Ocular involvement, Purulent bilateral conjunctivitis Systemic: Atypical pneumonia, Cold antibody haemolytic anaemia Mycoplasma pneumoniae B cell activation, AB production, Cutaneous immune complex deposition, Complement formation, Molecular mimicry in keratinocyte antigen and Mycoplasma adhesion molecules Clinical presentations, Radiological features of MP infection, Lack of culprit drug history in a pneumonia setting, Cold agglutinins, MP IgM antibody, Leukocytosis, Shift to the left, PCR Histopathology: Histopathological similarities to TEN Antibiotic therapySupportive careCorticosteroidsIVIG Antibiotic therapy Antibiotic therapy Supportive care Supportive care Corticosteroids Corticosteroids IVIG IVIG Mucocutaneous: Polymorphic, Maculopapular, Morbilliform, Diffuse erythroderma, Dry & red lips, Mucosal changes, Hand & feet erythema, Edema, Blistering skin lesions Systemic: Fever, Multisystem organ involvement, Laboratory evidence of hyperinflammatory response SARS‐COV2 TEN‐like clinical presentations in a setting of confirmed MIS‐C, Lack of culprit drug history Histopathology: Histopathological similarities to TEN Supportive careCorticosteroidsIVIGTocilizumabAtazanavir Supportive care Supportive care Corticosteroids Corticosteroids IVIG IVIG Tocilizumab Tocilizumab Atazanavir Atazanavir Two weeks after transplantation Mucocutaneous: Diffuse erythroderma, Bulla formation, Desquamation, Full‐thickness epidermal necrosis (Grade IV), Beginning from acral site & spreading proximally Systemic: Affecting Liver, Gut, Thymus Predominance of CD8+ T lymphocytes, GVHD has more inflammation than TEN does Histopathology: Skin biopsy has low sensitivity & specificity Supportive care Supportive care Corticosteroids Corticosteroids TNF antagonist TNF antagonist Mycophenolate Mofetil Mycophenolate Mofetil Antithymocyte Globulin Antithymocyte Globulin Anti‐il‐2r antibodies Anti‐il‐2r antibodies Phototherapy Phototherapy Without prodromal phase Mucocutaneous: Massive epidermal cleavage & cutaneous necrosis, Vesicobullous changes, Subepidermal blistering, Sun‐exposed area, Without target‐like lesions, Mucosal membrane involvement Systemic: Other presentations of lupus Clinical presentations, Absence of suitable drug consumption history, Laboratory data Histopathology: Basal layer vacuolation, Keratinocyte apoptosis, Full‐thickness epidermal necrosis, Dyskeratosis extending down adnexae, Presence of lupus band at the dermo‐epidermal junction in IHC, including granular IgG, IgM, C3 blinding Supportive care Supportive care Corticosteroids Corticosteroids IVIG IVIG Mycophenolate Mofetil Mycophenolate Mofetil Abbreviations: AGEP, acute generalized exanthematous pustulosis; DRESS, drug rash with eosinophilia and systemic symptoms; GBFDE, generalized bullous fixed drug eruption; GVHD, graft versus host disease; MIRM, mycoplasma‐induced rash and mucositis; MIS‐C, multisystem inflammatory syndrome in children; TEN, toxic epidermal necrolysis. Drug rash with eosinophilia and systemic signs (dress) Clinical manifestation DRESS syndrome, previously named drug hypersensitivity syndrome, is an intense and life‐threatening adverse reaction to medication. It is identified by dermatitis, fever, internal organ involvement and lymph node enlargement. Similar to TEN, DRESS typically occurs approximately 2–6 weeks after the culprit's drug consumption and has a prodromal phase. TEN‐like eruption and skin detachment are rarely present in severe cases of DRESS. 8 , 9 In DRESS, initially, the skin of acral parts, including the limbs and face, gets involved, whereas in TEN, manifestation first appears on the trunk. Mucosal involvement is more commonly and severely observed in TEN and is usually mild in DRESS. 8 Although organ injury is present in both conditions, severe liver and kidney involvement is more common in DRESS. 10 Despite potential complications of DRESS, like myocarditis, pericarditis, pneumonia and nephritis, reported mortality rates are higher in TEN. 8 , 9 Figure 1 illustrates a TEN‐like DRESS case with characteristic skin lesions (Figure 1 ). TEN‐like drug rash with eosinophilia and systemic signs (DRESS) syndrome: A 9‐year‐old girl with a history of cefixime consumption presenting with erythematous papules and blisters prominently in acral parts, positive Nikolsky's sign and facial oedema. Pathophysiology The primary drugs that cause DRESS are aromatic anticonvulsants such as phenytoin, phenobarbital and carbamazepine, as well as sulfonamides. Unlike TEN, infections and malignancies do not lead to DRESS. 8 , 9 , 10 DRESS as a systemic reaction involves the activation of drug‐specific T‐cells, which may be associated with reactivation of human herpesvirus‐6 (HHV‐6) and the body's immune response to the virus. Individuals with DRESS may have a positive patch test reaction to certain drugs and the presence of drug‐specific CD4+ and CD8+ T‐cells that produce TNF‐α and Interferon‐gamma (IFN‐γ). In the acute phase of DRESS, there is an increase in CD4+ and CD8+ T lymphocytes that express activation markers and display an altered antigen receptor repertoire. 11 , 12 DRESS may be linked to the HHV‐6 virus, and there is a debate on whether virus reactivation plays a role. 12 It is also suggested that immunodeficiency may trigger viral reactivation, with T regulatory cells and B cells increasing and immunoglobulin levels decreasing during the acute phase. This pathogenesis differs from TEN, which is mediated by drug‐specific expansion of CD8+ T lymphocytes and activation of the caspase cascade through perforin/granzyme or Fas–Fas ligand pathways leading to keratinocyte necrosis. 11 , 12 , 13 Diagnosis In the context of severe cutaneous drug reactions, DRESS is one of the differential diagnoses that should always be considered. While the ASAP phenomenon often brings TEN to mind, physicians must also consider other TEN‐like conditions such as DRESS. The onset of mucocutaneous signs can aid in diagnosis: DRESS initially presents in the acrofacial region, whereas TEN usually begins in the truncal area. 8 The most significant haematological finding in DRESS patients is eosinophilia (>500/mm3 or >10%), which is rarely seen in TEN. While leukocytosis and lymphocytosis are present in DRESS, leukopenia and lymphopenia are typically observed in TEN. Elevated liver enzymes are almost always seen in the DRESS condition, and they also usually might be presented in TEN. 8 , 14 Skin biopsy is a practical way to distinguish between TEN and typical DRESS, considering that TEN is characterized by full‐thickness and extensive keratinocyte necrosis, while DRESS does not show full‐thickness necrosis or sterile subcorneal pustules. Nevertheless, TEN‐like DRESS is associated with the extensive necrotic keratinocytes. 8 , 15 Treatment Similar to TEN, the first step in treatment is discontinuing the causative drug. Clinical symptoms are often resolved without sequelae after drug cessation. Supportive care is necessary, like TEN. Corticosteroids are the essential medications for treating DRESS. Prednisolone is prescribed at a moderate to high dose (40–50 mg/day) until clinical improvement and normalization of laboratory parameters. 11 , 16 In DRESS with organ involvement, second‐line treatments are indicated, including cyclosporine and IVIGs. However, the benefits of these therapies are controversial in TEN. 8 , 11 , 16 TEN‐LIKE GENERALIZED BULLOUS FIXED DRUG ERUPTION (GBFDE) Clinical manifestation Fixed drug eruptions (FDE) might present as a generalized bullous form (GBFDE), which can be mistaken for TEN. GBFDE typically affects at least three anatomical sites, including the head and neck, trunk, limbs and genitalia. GBFDE can present within 30 min to 1 day after drug consumption. Constitutional symptoms and toxic appearance are more commonly seen in TEN. The cutaneous involvement in GBFDE presents an underlying reddish‐brown to brownish‐grey discolouration and overlying bullae on diffuse hyperpigmentation. Mild mucous membrane involvement in only half of GBFDE patients can present. 17 , 18 , 19 , 20 Figure 2 illustrates a case of GBFDE with characteristic bullae and hyperpigmentation (Figure 2). TEN‐like generalized bullous form of fixed drug eruptions: Genitalia hyperpigmentation and widespread bullae formation in genitalia with large sheet‐like skin detachment in an 18‐year‐old man after consumption of Gelofen (Each capsule contains 325 mg of acetaminophen, ibuprofen 200 mg and 40 mg of caffeine). Pathophysiology Antibiotics like trimethoprim‐sulfamethoxazole, tetracycline, cephalosporins and penicillins, as well as NSAIDs and acetaminophen, are common causes of GBFDE. 21 In GBFDE, localized tissue damage secondary to hypersensitivity type IV to a culprit drug occurs. This reaction activates intradermal CD8+ T cells and releases mediators. When compared with TEN, GBFDE exhibits increased dermal CD4+ and Foxp3+ cell infiltration and fewer intraepidermal CD56+ and granulysin cells. However, intraepidermal CD31, CD41, CD8, dermal CD81 and CD561 cells are not different between TEN and FDE. 22 Diagnosis In GBFDE, lesions recur at the exact previous sites, which points to a specific diagnosis. 18 The time between drug consumption and eruption onset can be a diagnostic key, with lesions typically developing 30 minutes to 24 hours after taking the causative medication. 18 , 19 Nearly in one‐third of cases, a patch test at the previously involved site can identify the culprit drug. This could especially help in cases with unclear clinical history. 21 Histology investigations also help to differentiate GBFDE from TEN. In GBFDE, distinct apoptotic keratinocytes across the epidermis, noticeable infiltration of eosinophils and lymphocytes in the dermis, and the presence of dermal melanophages are notable characteristics. Conversely, TEN displays groupings of apoptotic keratinocytes, often accompanied by complete epidermal necrosis and a reduced number of eosinophils and dermal melanophages. The level of granulysin in TEN is high, and it can be used to differentiate these two conditions. 18 , 19 Treatment Similar to TEN, cessation of the medication that causes GBFDE is the first step in treating it. Supportive treatments like analgesics, emollients and antihistamines are the next step. 23 A short course of systemic corticosteroids is also used to treat GBFDE. There is no evidence to suggest that IVIG is effective in treating GBFDE. 19 , 23 ACUTE GENERALIZED EXANTHEMATOUS PUSTULOSIS (AGEP) Clinical manifestation AGEP, like TEN, is a severe and rare adverse cutaneous drug reaction. It is characterized by the rapid onset of numerous sterile pustules, as shown in Figure 3, with acute mucocutaneous eruption. In AGEP, the cutaneous presentations appear about 24 h after the culprit's drug consumption. Numerous small, non‐follicular, sterile pustules on an erythematous and edematous background are the hallmarks of AGEP. In some cases, widespread pustules might join together, creating a clinical resemblance to TEN. The coalescence of numerous pustules can result in a pseudo‐positive Nikolsky's sign in some AGEP patients. 24 , 25 Leukocytosis and fever are frequently seen in AGEP. 26 , 27 Systemic involvement might rarely be seen in elderly patients with comorbidities. 28 , 29 Figure 3 illustrates a case of AGEP with truncal and proximal limb erythroderma and numerous vesiculobullous eruptions with pseudo‐positive Nikolsky's sign and large sheet skin detachment (Figure 3). TEN‐like acute generalized exanthematous pustulosis: A 3‐year‐old girl with a history of acetaminophen consumption presenting with truncal and proximal limb erythroderma and numerous vesiculobullous eruptions with pseudo positive Nikolsky's sign and large sheet skin detachment. Pathophysiology Antibiotics, NSAIDs, opioids, anticonvulsants, hydroxychloroquine, and chemotherapy agents trigger AGEP. Although offended drugs in AGEP are similar to TEN, hallmarked drugs in TEN are anticonvulsants, allopurinol and antibiotics such as sulfonamides. 25 The exact pathophysiology of AGEP, similar to TEN, needs further investigation. Both conditions are T‐cell‐mediated type IV hypersensitivity reactions. TEN represents a type IVc cytotoxic reaction, with CD8+ cytotoxic killer cells playing a crucial role. Meanwhile, AGEP is associated with a type IVd reaction involving the production of chemokines that attract neutrophils. 30 Diagnosis AGEP is diagnosed clinically and can be distinguished from TEN based on its clinical manifestation and period difference of signs after the culprit drug consumption. Skin biopsies may be beneficial in atypical cases. The histological sample from AGEP displays spongiform subcorneal and intraepidermal pustules, dermal oedema, necrosis of individual keratinocytes, and an accumulation of neutrophils and eosinophils around blood vessels. On the other hand, the histology sample of TEN demonstrates keratinocyte necrosis around blood vessels, as well as a distinct inflammatory infiltration of lymphocytes and histiocytes in the superficial dermis, with or without subepidermal bullae. 25 Treatment While TEN is life‐threatening and can have long‐term complications, even TEN‐like AGEP cases have a benign course. The condition improves 2 weeks after stopping the offending medication. In AGEP, hemodynamic instability is rare. 25 Systemic involvement and extensive skin detachment require admission to the intensive care unit, as is typically observed in TEN. Additionally, the use of corticosteroids shortens the duration of hospitalization. 25 TEN‐LIKE METHOTREXATE‐INDUCED TOXICITY Clinical manifestation Methotrexate (MTX) has been associated with various mucocutaneous adverse effects, particularly in a high‐dose therapeutic regimen. Such dosing increases the risk of toxicity and may lead to generalized painful skin erosion resembling TEN. 31 The early signs include painful skin and mucosal erosions in association with pancytopenia. In contrast to TEN, MTX‐induced toxicity typically presents multiple skin detachments without typical target‐like lesions. 32 Pathophysiology The aetiology of TEN‐like presentation induced by MTX remains uncertain, with ongoing debate over whether it is an allergic or dose‐related toxicity reaction. 32 However, evidence suggests a predisposition towards dose‐related toxicity. Therefore, attention is needed to prevent toxicity, particularly in high‐dose therapeutic regimens. 33 In contrast to the inflammatory‐mediated skin eruptions seen in SJS/TEN, MTX‐induced toxicity does not show an upregulation of inflammatory mediators. 32 Limited cases of TEN‐like conditions have been reported in low‐dose therapeutic regimens, especially in those with underlying skin conditions. In patients with underlying dermatologic conditions, such as psoriasis and bullous pemphigoid, the administration of MTX increases the risk of TEN‐like presentations. It seems that psoriatic keratinocytes are more susceptible to MTX toxicity. It is suggested that the presence of cutaneous conditions increases the risk of MTX‐induced TEN‐like reactions. 31 , 34 Diagnosis The diagnosis of MTX toxicity is linked to a comprehensive evaluation of the patient's drug history. A crucial determinant in diagnosing MTX toxicity is the examination of MTX usage, particularly within a high‐dose therapeutic regimen. In histopathology, TEN‐like MTX toxicity exhibits dyskeratosis, leading to epidermal necrosis, similar to TEN. MTX‐induced toxicity manifests as non‐specific keratinocyte dystrophy, while SJS/TEN shows cytotoxic T lymphocyte‐mediated keratinocyte necrosis. MTX‐induced toxicity is marked by epidermal atrophy, either with or without ulceration. Conversely, SJS/TEN shows no epidermal atrophy but demonstrates subepidermal vesiculation. 32 Treatment Treatment has three major clinical steps: (1) withdrawing the MTX, (2) MTX toxicity rescue, and (3) supportive care, similar to other TEN‐like conditions. 31 , 33 In the context of high‐dose MTX therapy, Leucovorin is FDA‐approved as part of the treatment to reduce the toxic effects of MTX. The conventional method of administration for Leucovorin is 20 mg 6 hourly on day 1, followed by 10 mg 6 hourly until the blood component reaches the normal range. 35 Rehydration also helps to improve the excretion rate. 36 Carboxypeptidase can be an alternative option to Leucovorin. 31 Using granulocyte‐colony stimulating factor (G‐CSF) in the context of MTX‐induced bone marrow toxicity and leukopenia is controversial but suggested to beneficiate undesirable side effects. 36 IVIG has not been utilized for treating TEN‐like reactions induced by MTX therapy. Systemic steroids or immunosuppressive drugs are not indicated in TEN‐like MTX toxicity, unlike in TEN. MUCOCUTANEOUS MUSTARD GAS TOXICITY Clinical manifestation Sulphur mustard (SM) gas, a chemical weapon, can induce a range of symptoms based on the extent of exposure. These can include respiratory, mucocutaneous and gastrointestinal issues such as rhinorrhea, epistaxis, dyspnea, pulmonary edema, nausea, vomiting, abdominal pain, dysentery and severe dehydration. 37 , 38 , 39 The initial cutaneous symptoms are an oily substance on the skin. Within 2–10 h after exposure, pruritus and light erythema might develop, which simulate sunburn. 40 , 41 Bullae, erythema and necrosis, which typically affect the areas of the body with folds, such as the groin and genitalia, are the next presentations. 37 , 38 , 40 , 41 , 42 In addition, urogenital mucosal and ocular involvement can also mimic the TEN. 40 Pathophysiology SM can be transmitted through inhalation and contact with contaminated surfaces. When the temperature falls below 14C, SM can take on a liquid form, often resulting in skin damage. Conversely, when the temperature rises above 14C, the liquid form of SM turns into a vapour, causing damage to the respiratory tract, eyes and skin. 37 , 38 SM damages DNA through alkylation, activating apoptosis and necrosis pathways in keratinocytes. Additionally, SM gas triggers oxidative stress, forming reactive oxygen species (ROS) while concurrently inhibiting antioxidant enzymes. SM can destroy intracellular adhesions of epithelial cells, involving proteins such as laminin‐5. Cytokines, including interleukin‐1 (IL‐1), IL‐6, IL‐8, TNF‐ α and IFN‐γ, play pivotal roles in mediating the injuries induced by SM. In contrast to TEN, in SM toxicity, capillary thrombi located beneath vesicular formations and disruption of capillary wall integrity lead to signs of necrosis. 43 , 44 Diagnosis The identification of mucocutaneous mustard gas toxicity relies on the circumstances of SM exposure and the quick development of clinical symptoms. Nevertheless, TEN almost happens after administering specific medications and with a delay phase. 41 Treatment An effective antidote for SM exposure is unavailable. Therefore, the best treatment is prevention. As the first step, the patient must be swiftly removed from the attack scene. Before transporting the victim to the hospital, the victim should be thoroughly cleaned with 0.5% hypochlorite, running water, or soap and water for a long time. 44 , 45 As SM can spread to various surfaces and the surrounding environment, it is crucial to decontaminate all surfaces to prevent further contaminant spreading. Antibiotics such as silver sulfadiazine are used in the hospital to treat skin lesions and prevent infection in the affected areas. Administering analgesics, antihistamines, and topical or systemic antipruritics may be necessary. Topical corticosteroids are effective in alleviating irritation and reducing swelling in the affected area. 38 , 44 , 45 , 46 PSEUDOPORPHYRIA Clinical manifestation Bullous dermatosis associated with haemodialysis rarely manifests with profound, painful blisters on the fingertips and sun‐exposed areas, occasionally evolving into a widespread necrobullous eruption resembling TEN. 3 Comparable to TEN, involvement of mucous membranes occurs, albeit less aggressively, and a prodromal phase is typically absent. Bullous formations are localized primarily on sun‐exposed regions, frequently observed on the dorsum of the hands and fingers. 3 , 47 Pathophysiology The exact mechanism underlying its pathogenesis remains unclear. Various factors have been discussed to have a correlation with pseudoporphyria, which among the most common causes were medications, including NSAIDs, furosemide, nalidixic acid, tetracycline, pyridoxine, isotretinoin and tyrosine kinase inhibitors like imatinib. 3 , 48 , 49 Diagnosis Characteristic histopathological findings include inflammatory infiltration, thickening of venular walls with deposition of immunoglobulins, and presence of C3 and IgG deposition at the epidermal‐dermal junction. 47 Additionally, subepidermal bullae with a corrugated base are observed. Measurements of porphyrin levels in serum, urine and faeces often yield normal results. 49 However, the determination of the serum/faecal porphyrin fraction rate might aid in the diagnostic process. 47 Treatment Treatment modalities for pseudoporphyria typically involve supportive care, the administration of N‐acetylcysteine, cessation of suspected triggering agents and the implementation of sun protection measures, particularly targeting UVA wavelengths. 3 , 49 MYCOPLASMA PNEUMONIAE‐INDUCED RASH AND MUCOSITIS (MIRM) Clinical manifestation Mycoplasma pneumoniae (MP) infection can occasionally cause mucocutaneous involvement, which is called MIRM. Usually, the MIRM lesions are prominent severe mucositis in association with oral ulcer and erosion, resembling SJS. Typically, cutaneous involvement is uncommon. When cutaneous involvement occurs, the lesions can be presented in different ways, such as macules, papules, atypical targetoids or vesiculobullous lesions. Generalized vesiculobullous lesions with severe oral involvement might bring a TEN‐like condition to mind. 5 , 50 , 51 , 52 In Figure 4, the characteristic mucosal involvement in MIRM is evident (Figure 4). TEN‐like mycoplasma pneumoniae‐induced rash and mucositis: Prominent oral mucosa involvement with necrotic ulcers and diffuse patchy form erythroderma in two children with mycoplasma pneumonia infection. MIRM is more prevalent in young men and children than TEN, which is more common in adults. As with TEN, MIRM has a prodromal phase. Nevertheless, the main clinical course is milder than TEN, with a better prognosis. MP is typically associated with atypical pneumonia and cold antibody haemolytic anaemia. Conversely, clinical presentations of TEN do not exhibit these features. 53 Pathophysiology The exact pathophysiology of MIRM is unclear. 50 One suggested hypothesis regarding mucocutaneous manifestations associated with MP infection is B cell activation and antibody production, which may lead to cutaneous immune complex deposition and complement formation. Another suggested hypothesis is the possibility of molecular mimicry in keratinocyte antigen and Mycoplasma adhesion molecules. These proposed mechanisms differ entirely from hypersensitivity type IV in SJS/TEN. 30 , 51 , 52 Diagnosis The MIRM diagnosis is based on clinical and investigational features of MP infection. Lack of culprit drug history in a pneumonia setting is a helpful clue for diagnosing MIRM. Laboratory data can be gathered through serum analysis for cold agglutinins, enzyme‐linked immunoassays (ELISA) and MP IgM antibody levels. 51 , 53 Leukocytosis with a shift to the left is also present in MIRM, whereas usually lymphopenia is present in TEN. 50 Bullae tissue culture and polymerase chain reaction (PCR) can also assist in diagnosing MIRM. Due to the histopathological similarities between MIRM and TEN, a histological investigation might not be helpful. 5 , 51 , 54 Treatment Treatment should consist of both pulmonary and extrapulmonary management in MIRM. Initially, antibiotics are administered empirically to children who exhibit community‐acquired pneumonia. Treatment of the skin lesions should consist of supportive care. IVIG at 1 g/kg/day for three days can accelerate recovery and dissolve the lesion. 53 Systemic corticosteroids are often prescribed to patients with significant mucosal involvement in MIRM to reduce inflammation and alleviate pain, while their use in TEN is controversial. 52 TEN‐LIKE MULTISYSTEM INFLAMMATORY SYNDROME IN CHILDREN ASSOCIATED WITH COVID‐19 Clinical manifestation Children with multisystem inflammatory syndrome (MIS‐C) present with fever, involvement of multiple organs and laboratory indications of a hyperinflammatory response to the severe acute respiratory syndrome Coronavirus 2 (SARS‐COV2). 55 MIS‐C with Kawasaki features can resemble Kawasaki disease. 56 The most commonly reported eruptions in MIS‐C with Kawasaki features are polymorphic, maculopapular, morbilliform, widespread erythroderma, erythema and oedema of the hands and feet, as well as dry and red lips, and other changes in the mucous membranes. 55 , 56 , 57 , 58 Rarely, mucocutaneous manifestations may be as severe as TEN. In MIS‐C, similar to TEN, the primary symptoms are the presence of blistering skin lesions and mucosal involvement. 55 , 56 Figure 5 shows the diverse cutaneous manifestations of MIS‐C, including skin discoloration with sheet‐like skin detachment with mucosal involvement that can resemble TEN in severe cases (Figure 5). TEN‐like multisystem inflammatory syndrome in children (MIS‐C): A 5‐year‐old boy with history of COVID pneumonia who developed MIS‐C. Acrofacial skin discoloration with sheet‐like skin detachment with mucosal involvement. Pathophysiology The pathogenesis of MIS‐C in COVID‐19 patients is still uncertain. Evidence suggests it may be due to immune dysregulation after the viral infection. Some patients with MIS‐C have a positive test for anti‐SARS‐CoV‐2 antibodies but not for the virus itself. It is hypothesized that MIS‐C may result from the SARS‐CoV‐2 virus's ability to suppress certain immune responses, leading to uncontrolled viral growth. 55 Although the most reported cause of TEN is drug‐induced TEN, idiopathic cases where no particular drug is responsible can be identified. Infections such as SARS‐COV2 are a trigger of severe mucocutaneous reactions. However, it is unclear whether this is a TEN condition due to infectious causes or a MIS‐C with TEN presentations. Studies suggest that due to different management of the immune system in drug‐induced TEN and infection‐induced one, we should distinguish the aetiology of this condition to have a better outcome. 59 Diagnosis Clinical evidence of the blistering skin lesions and mucosal involvement in the setting of a diagnosis of MIS‐C and lack of evidence of previous drug consumption that might have triggered the eruption can be considered as TEN‐like MIS‐C. Although few studies believe that the skin manifestations of MIS‐C may mimic SJS/TEN and DRESS and are differentiable by biopsy, approaching and managing a TEN‐like case of MIS‐C more conservatively can lead to a better prognosis. MIS‐C predominantly involves inflammatory processes and vasculopathy affecting multiple organs, whereas TEN is characterized by extensive skin necrosis with minimal inflammation and significant keratinocyte apoptosis. It should be noted that unlike TEN, cardiac involvement is frequently observed in those with MIS‐C. 56 , 60 , 61 Treatment Comprehensively, the mainstay treatment of TEN‐like MIS‐C is similar to classic TEN with systemic steroids and IVIG. Additional treatments are Tocilizumab, Atazanavir and Infliximab. 56 , 60 , 62 The first reports of MIS‐C cases with TEN‐like manifestation included two patients with this condition, as reported by B. Katlan and colleagues. Among their study, one of the patients who received early Tocilizumab therapy had a more favourable clinical outcome. This indicates that administering Tocilizumab early is important for managing both MIS‐C and SJS‐related cytokine storms. 60 Also, Karimi A. et al. reported that because of their local guideline, Atazanavir was added to the mainstay treatment with considerable improvement in their patient clinical course. 56 However, because of the limited data available, there is no definitive treatment for MIS‐C. SEVERE GVHD AS A TEN‐LIKE CONDITION Clinical manifestation GVHD can occur in individuals who have undergone allogeneic stem cell or bone marrow transplantation. One of the clinical symptoms of this disease is cutaneous GVHD, which can be classified as chronic or acute. The acute form of the disease occurs after 2 weeks of transplantation. Grade IV GVHD represents a severe form of acute GVHD and is identified by widespread redness of the blister formation and shedding of the skin. Mild acute GVHD is distinct from TEN and can be easily differentiated. 63 However, Grade IV GVHD, related to full‐thickness epidermal necrosis, is highly similar to TEN, making it challenging to distinguish between the two clinically. Unlike TEN, GVHD begins after bone marrow transplantation. Gastrointestinal symptoms such as diarrhoea are more common in GVHD compared with TEN. Liver involvement, which includes increased bilirubin, is also seen in GVHD. Although mucosal involvement may be seen in severe GVHD, it may be less prominent than TEN. 64 , 65 Figure 6 demonstrates a TEN‐like presentation of GVHD in a 5‐year‐old boy with a history of bone marrow transplantation two weeks prior for acute lymphocytic leukaemia (Figure 6). TEN‐like graft versus host disease (GVHD): A 5‐year‐old boy with a history of two‐week prior bone marrow transplantation in the context of acute lymphocytic leukaemia presenting with diffuse skin discoloration and sheet‐like skin detachment as a grade IV GVHD. Pathophysiology After transplantation, donor T lymphocytes migrate to lymphoid tissues, triggering the innate immune response. IL‐1, TNF, IL‐6 and IFN initiate this response. Donor and host antigen‐presenting cells detect histocompatibility disparity and activate alloreactive T lymphocytes. Subsequently, cytotoxic effector T cells leave lymphoid tissues and target organs such as the skin, liver, gut and thymus, leading to tissue damage. 66 These two diseases are very similar immunologically. 67 A predominance of CD8+ T lymphocytes characterizes both diseases, but TEN has a higher ratio of CD8+/CD4+, and GVHD has more inflammation than TEN does. 68 TNF‐α also is highly present in both diseases. 69 Diagnosis The most common sign of acute GVHD is cutaneous manifestations, and diagnosis depends on clinical presentation. 66 The distribution of lesions is one of the clinical differences between these two acute severe GVHD and TEN. Acute severe GVHD lesions start from the extremities and then spread to the body, while TEN lesions start from the trunk and then spread to the extremities. 67 As skin biopsy has low sensitivity and specificity, it should be used only in atypical cases and based on the clinical courses of the disease. 70 Treatment The initial treatment for acute severe GVHD is intravenous methylprednisolone at a dose of 2 mg/kg/day. If the patient does not show improvement within 3 days or fails to respond after 5–7 days of treatment combined with calcineurin inhibitors (CNIs), second‐line therapies are considered. Extracorporeal photopheresis (ECP), Mycophenolate Mofetil, TNF antagonist (Infliximab, Etanercept), Antithymocyte Globulin (ATG) and Anti‐il‐2r antibodies are the second‐line therapies. Phototherapy is an option for acute GVHD steroid‐refractory and steroid‐dependent patients if the disease only affects the skin. 66 TEN‐LIKE LUPUS Clinical manifestation TEN‐like lupus is a rare but life‐threatening condition in the setting of the bullous form of systemic lupus erythematosus (SLE). The cutaneous hallmark is vesicobullous changes with subepidermal blistering in the absence of target‐like lesions. Nikolsky's sign can be present or not. The massive epidermal cleavage and necrosis of the cutaneous may resemble TEN and other TEN‐like diseases. However, classic lupus manifestations, such as systemic involvement and laboratory data, and the absence of suitable drug consumption history can lead to the differentiation between TEN and other TEN‐like diseases. 3 , 71 , 72 , 73 Compared with TEN, the course of eruption in TEN‐like lupus is much slower. The mucosal involvement, which is occasionally in bullous LE, is involved nearly in all cases but far less than TEN. 72 , 74 Figure 7 illustrates the extensive vesicobullous eruptions and dusky‐red vesiculobullous lesions seen in TEN‐like lupus, underscoring the need for careful differential diagnosis (Figure 7). TEN‐like lupus: A 9‐year‐old girl with generalized vesicobullous eruptions and dusky‐red vesiculobullous eruptions in the absence of target‐like lesions with positive Nikolsky's sign. Because of patients' ultraviolet susceptibility, lesions and bullae are initially anticipated to present in the sun‐exposed area. Nevertheless, as the disease course intensifies, the lesions may spread throughout the body and mislead the diagnostic process. Despite TEN, a flu‐like prodrome is not usually presented. 71 , 73 Pathophysiology The proposed mechanism for the similarity between TEN‐like lupus and classic TEN involves an increase in interleukin 6 and interleukin 10 levels, upregulation of Fas and Fas–Fas ligand interactions, and the role for cytotoxic and autoimmune T cells in the setting of cytokine release. 72 , 74 Patients with Bullous LE may be separated into two groups based on their presentation. The first category is characterized by an interface pattern featuring mostly T‐lymphocytic infiltration. It might display localized blistering within current LE lesions or exhibit TEN‐like LE with limited signs of underlying LE activity. The second category manifests as subepidermal blistering associated with a neutrophilic infiltrate and antibodies to type VII collagen and is commonly known as bullous LE. 72 Diagnosis There is a debate about whether some cases of TEN in the LE context are misclassified because of the higher incidence of SJS/TEN in these patients. ASAP manifestation in LE can be either the patient's first presentation of LE or in the course of the disease with a confirmed diagnosis of SLE in advance, while multiple medications have been taken in the acute flares of LE. The last one complicates the diagnosis process. 3 , 72 , 73 , 74 , 75 The clinical course of the disease, which is slower in association with the absence of targetoid lesions and systemic clinical manifestation of LE, is helpful in diagnosis. Physicians should also pay attention to the analysis of laboratory data if the clinical presentation is favourable to LE. 72 , 74 Histological examination of TEN‐like lupus may reveal similar features to classic TEN, including basal layer vacuolation, keratinocyte apoptosis and full‐thickness epidermal necrosis with dyskeratosis extending down adnexa. 71 , 74 However, distinguishing features of LE may be present, such as the presence of a lupus band including granular IgG, IgM and C3 binding at the dermo‐epidermal junction on direct immunofluorescence, indicating the potential utility in this clinical situation to differentiate these conditions. 3 , 72 , 74 Rowell Syndrome, or erythema multiform‐like cutaneous eruption in the setting of SLE, is also one of the other differential diagnoses if the anti‐Ro antibody is positive. However, with mucosal and full‐body involvement and only a solitary episode of dermatosis, this diagnosis can also be excluded. 71 , 73 It is believed that Rowell syndrome and TEN‐like lupus may be components of the same spectrum of illness. Laboratory findings such as positive ANA, anti‐dsDNA and anti‐Ro support the diagnosis of SLE. 3 , 71 Overall, the diagnosis seems challenging and requires clinical susceptibility and multiple acute support for each possible diagnosis. It may also become even more difficult when the course of the disease becomes subacute. 74 , 75 Treatment TEN‐like lupus requires intensive supportive care similar to TEN, including fluid management, wound care and infection control in a specialized unit. Prompt multidisciplinary treatment is essential for improving patient outcomes. Patients with this condition should receive care from rheumatologists to ensure the best possible outcome. The guidelines from the British Society for Rheumatology suggest using intense immunosuppression to both induce and maintain remission in cases of acute severe lupus. Systemic corticosteroids alone or in combination with IVIG with a dose of 0.75–2 g/kg/day and mycophenolate mofetil are the reported treatment in TEN‐like lupus patients. 71 However, the prescription of mycophenolate mofetil may be doubtful due to the possibility of causing TEN. 71 , 72 , 73 CONCLUSION In conclusion, the evaluation and diagnosis of conditions presenting with extensive skin detachment and a positive Nikolsky's sign, such as TEN, require careful consideration of the patient's history and clinical context. The absence of a history of culprit drug intake should prompt clinicians to explore other differential diagnoses beyond TEN. Each condition within the differential diagnoses, such as DRESS, TEN‐like lupus and AGEP, presents unique clinical features and aetiologies, which necessitate thorough assessment to ensure accurate diagnosis and appropriate management. Misdiagnosing TEN‐like conditions can lead to inappropriate treatment and worsen the patient's condition. Accurate diagnosis is crucial, as it directly influences patient outcomes and ensures timely, effective interventions. The complexity of these cases underscores the importance of multidisciplinary approaches and the need for continued research to refine diagnostic criteria and treatment protocols for these life‐threatening conditions. CONFLICT OF INTEREST STATEMENT The authors have confirmed that they do not have any conflicts of interest that could potentially influence the research objectives, authorship or publication of this article.